<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-31T18:50:02Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/39919" metadataPrefix="rdf">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/39919</identifier><datestamp>2026-02-03T10:51:43Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:riuma.uma.es:10630/39919">
      <dc:title>Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure</dc:title>
      <dc:creator>De-Vivero-de-Porras, María del Carmen</dc:creator>
      <dc:creator>Sanjuán-Muñoz, Enrique</dc:creator>
      <dc:subject>Competencia económica desleal</dc:subject>
      <dc:subject>Industria farmacéutica</dc:subject>
      <dc:subject>Medicamentos -- Legislación</dc:subject>
      <dc:subject>Medicamentos -- Derecho</dc:subject>
      <dc:subject>Derecho mercantil</dc:subject>
      <dc:subject>Comercio -- Regulación</dc:subject>
      <dc:subject>Patentes -- Derecho</dc:subject>
      <dc:description>On October 21, 2022, the Spanish Competition Agency (CNMC) sanctioned the North American pharmaceutical company Merck Sharp &amp; Dohme for abuse of a dominant position. The practice for which it was finally sanctioned consisted of the adoption of a strategy aimed at delaying and making it difficult for another company to enter the Spanish medicines market in order to protect sales for a product marketed exclusively by that company and for which had a patent. This paper analyzes this resolution in an attempt to delimit the difference between the legitimate exercise of the right to effective judicial protection and its abuse.</dc:description>
      <dc:date>2025-09-16T06:24:32Z</dc:date>
      <dc:date>2025-09-16T06:24:32Z</dc:date>
      <dc:date>2025-07-28</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>de Vivero de Porras C, Sanjuán y Muñoz E. Abuse of Dominant Position, Effective Judicial Protection and Abuse of Procedure. Journal of Law, Medicine &amp; Ethics. 2025;53(3):379-387. doi:10.1017/jme.2025.10145</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10630/39919</dc:identifier>
      <dc:identifier>10.1017/jme.2025.10145</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>open access</dc:rights>
      <dc:rights>Atribución 4.0 Internacional</dc:rights>
      <dc:publisher>Cambridge University Press</dc:publisher>
   </ow:Publication>
</rdf:RDF>
</metadata></record></GetRecord></OAI-PMH>